EOLS Q4 2024 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$79M+29.4% YoY

Gross Profit

$50M63.8% margin

Operating Income

-$2M-2.9% margin

Net Income

-$7M-8.6% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+29.2%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$3M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$233M

Total Liabilities

$227M

Stockholders' Equity

$6M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$79M	$61M	+29.4%
Gross Profit	$50M	$39M	+29.8%
Operating Income	-$2M	-$9M	+73.2%
Net Income	-$7M	-$12M	+42.6%

Revenue Segments

Product

$79M100%